Aromatase inhibitors - Socio-economical issues

Journal of Steroid Biochemistry and Molecular Biology

Volumn 95, Issue 1-5, 2005, Pages 137-142

  Lønning, Per E ^a   Geisler, Jürgen ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Aromatase; Inhibitor breast cancer pharmacoeconomics; QALY

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH CARE COST; HORMONAL THERAPY; INCIDENCE; METASTASIS; OSTEOLYSIS; PALLIATIVE THERAPY; POSTMENOPAUSE; RISK ASSESSMENT; SOCIOECONOMICS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG COSTS; HUMANS; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 23844539069     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.04.006     Document Type: Conference Paper

References (48)

1. P.E. Lønning Aromatase inhibitors in breast cancer End-Rel Cancer 11 2004 179 189
2. J. Bonneterre, A. Buzdar, J.-M. Nabholtz, J. Robertson, B. Thürlimann, and M. von Euler Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2001 2247 2258
3. H. Mouridsen, M. Gershanovick, Y. Sun, R. Perez-Carrion, C. Boni, and A. Monnier Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group J. Clin. Oncol. 21 2003 2101 2109
4. R. Paridaens, P. Therasse, L. Dirix, L. Beex, M. Piccart, and D. Cameron First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomized phase III trial of the EORTC Breast Group Proc. Am. Soc. Clin. Oncol. 23 2004 6 (Abstract 515)
5. P.E. Lønning Pharmacology of new aromatase inhibitors Breast 5 1996 202 208
6. M. Dowsett, A. Jones, S.R.D. Johnston, S. Jacobs, P. Trunet, and I.E. Smith In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer Clin. Cancer Res. 1 1995 1511 1515
7. ®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer Br. J. Cancer 74 1996 1286 1291
8. J. Geisler, N. King, G. Anker, G. Ornati, E. DiSalle, and P.E. Lønning In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients Clin. Cancer Res. 4 1998 2089 2093
9. J. Geisler, B. Haynes, G. Anker, M. Dowsett, and P.E. Lønning Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study J. Clin. Oncol. 20 2002 751 757
10. M. Baum, A.U. Buzdar, J. Cuzick, J. Forbes, J. Houghton, and Klijn JGM Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
11. P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, and M.J. Piccart A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N. Engl. J. Med. 349 2003 1793 1802
12. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, and T. Delozier A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N. Engl. J. Med. 350 2004 1081 1092
13. C.C. Earle, R.H. Chapman, C.S. Baker, C.M. Bell, P.W. Stone, and E.A. Sandberg Systematic overview of cost-utility assessments in oncology J. Clin. Oncol. 18 2000 3302 3317
14. J.F. Corry, and P.E. Lønning Systemic therapy in breast cancer: efficacy and cost utility PharmacoEconomics 5 1994 198 212
15. M.F. Drummond, G.L. Stoddart, G.W. Torrance. Methods for the Economic Evaluation of Health Care Programmes, Oxford Med Publ, Oxford, New York, Toronto, 1987.
16. M.A.G. Sprangers, and N.K. Aaronson The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review J. Clin. Epidemiol. 45 1992 743 760
17. M.L. Slevin, L. Stubbs, H.J. Plant, P. Wilson, W.M. Gregory, and P.J. Armes Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public Br. Med. J. 300 1990 1458 1460
18. T.J. Smith, and B.E. Hillner The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women J. Clin. Oncol. 11 1993 771 776
19. R.J. Epstein Does the breast cancer dollar makes sense? Eur. J. Cancer 28 1992 486 491
20. A. Laupacis, D. Feeny, A.S. Detsky, and P.X. Tugwell How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Can. Med. Assoc. J. 146 1992 473 481
21. B.E. Hillner, and T.J. Smith Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer N. Engl. J. Med. 324 1991 160 168
22. B.E. Hillner, T.J. Smith, and C.E. Desch Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model Breast Cancer Res. Treat. 25 1993 97 105
23. C.E. Desch, B.E. Hillner, T.J. Smith, and S.M. Retchin Should elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes J. Clin. Oncol. 11 1993 777 782
24. M. Drummond, E. Thompson, A. Howell, W. Jonat, A. Buzdar, and J. Brown Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer J. Drug Assess. 2 1999 169 179
25. B.E. Hillner, and D. Radice Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma Cancer 91 2001 484 489
26. G. Dranitsaris, P. Leung, J. Mather, and A. Oza Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate Anti Cancer Drug 11 2000 591 601
27. A.L. Jones, T.J. Powles, M. Law, A. Tidy, E. Easton, and R.C. Coombes Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years J. Clin. Oncol. 10 1992 1547 1552
28. F. Boccardo, A. Rubagotti, D. Amoroso, M. Mesiti, D. Romeo, and C. Caroti Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study J. Clin. Oncol. 19 2001 4209 4215
29. Atac Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - results of the ATAC (arimidex, tamoxifen alone or in comhination) trial efficacy and safety update analyses Cancer 98 2003 1802 1810
30. T.J. Powles, T. Hickish, J.A. Kanis, A. Tidy, and S. Ashley Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women J. Clin. Oncol. 14 1996 78 84
31. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, and W.M. Cronin Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 90 1998 1371 1388
32. E.A. Lien, E. Solheim, and P.M. Ueland Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment Cancer Res. 51 1991 4837 4844
33. P.E. Lønning, J. Geisler, L. Krag, L. Ottestad, Y. Bremnes, and H. AI Effect of exemestane on bone: a randomized placebo controlled study in postmenopausal women with early breast cancer at low risk Proc. Am. Soc. Clin. Oncol. 23 2004 6 (Abstract 518)
34. S.R. Cummings, D. Bates, and D.M. Black Clinical use of bone densitometry - scientific review JAMA 288 2002 1889 1897
35. B. Fisher, J. Dignam, N. Wolmark, D.L. Wickerham, E.R. Fisher, and E. Mamounas Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 353 1999 1993 2000
36. T. Powles, R. Eeles, S. Ashley, D. Easton, J. Chang, and M. Dowsett Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial Lancet 352 1998 98 101
37. U. Veronesi, P. Maisonneuve, A. Costa, V. Sacchini, C. Maltoni, and C. Robertson Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women Lancet 352 1998 93 97
38. J. Cuzick, J. Forbes, R. Edwards, M. Baum, S. Cawthorn, and A. Coates First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial Lancet 360 2002 817 824
39. J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, and S. Ashley Overview of the main outcomes in breast-cancer prevention trials Lancet 361 2003 296 300
40. T.J. Smith, and B.E. Hillner Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women J. Clin. Oncol. 18 2000 284 286
41. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, and J.A. Cauley The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial JAMA 281 1999 2189 2197
42. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 1992 1 15
43. T.J. Key, P.N. Appleby, G.K. Reeves, A. Roddam, J.F. Dorgan, and C. Longcope Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women J. Natl. Cancer Inst. 95 2003 1218 1226
44. T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, and H. Johnsen Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc. Natl. Acad. Sci. 98 2001 10869 10874
45. T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J.S. Marron, and A. Nobel Repeated observation of breast tumor subtypes in independent gene expression data sets Proc. Natl. Acad. Sci. U.S.A. 100 2003 8418 8423
46. M.J. Ellis, A. Coop, B. Singh, L. Mauriac, A. LlombertCussac, and F. Janicke Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J. Clin. Oncol. 19 2001 3808 3816
47. X.J. Ma, Z.C. Wang, P.D. Ryan, S.J. Isakoff, A. Barmettler, and A. Fuller A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 2004 607 616
48. P.E. Lønning Genes causing inherited cancer as beacons identifying the mechanisms of chemoresistance Trends Mol. Med. 10 2004 113 118